胰高血糖素样肽-1与肠道疾病
GLP-1 and Intestinal Diseases.
作者信息
Hunt Jenna Elizabeth, Holst Jens Juul, Jeppesen Palle Bekker, Kissow Hannelouise
机构信息
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
出版信息
Biomedicines. 2021 Apr 5;9(4):383. doi: 10.3390/biomedicines9040383.
Abstract
Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1's influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
摘要
越来越多的证据表明，胰高血糖素样肽-1（GLP-1）除了维持血糖外，在胃肠道中也具有有益作用。在此，我们综述了有关将GLP-1作为肠道疾病新疗法的最新研究数据，这些疾病包括炎症性肠病、短肠综合征、肠道毒性和乳糜泻。这些疾病可能的有益机制包括GLP-1对胃排空的影响、其抗炎特性及其肠营养作用。目前的知识基础来自实验动物和小型临床试验中可用的GLP-1激动剂治疗。然而，包括双GLP-1/GLP-2激动剂在内的新策略也正在开发用于治疗肠道疾病。
相似文献
1
GLP-1 and Intestinal Diseases.胰高血糖素样肽-1与肠道疾病
Biomedicines. 2021 Apr 5;9(4):383. doi: 10.3390/biomedicines9040383.
2
Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.新型胰高血糖素样肽-1/胰高血糖素样肽-2共激动剂对小鼠肠道容积有显著影响，并改善血糖控制。
Physiol Behav. 2018 Aug 1;192:72-81. doi: 10.1016/j.physbeh.2018.03.004. Epub 2018 Mar 11.
3
Emerging treatment options for short bowel syndrome: potential role of teduglutide.短肠综合征的新兴治疗选择：替度鲁肽的潜在作用
Clin Exp Gastroenterol. 2011;4:189-96. doi: 10.2147/CEG.S13906. Epub 2011 Aug 19.
4
Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome.胰高血糖素样肽-2与表皮生长因子联合给药对短肠综合征新生仔猪肠道适应性的协同作用。
Am J Physiol Gastrointest Liver Physiol. 2017 Apr 1;312(4):G390-G404. doi: 10.1152/ajpgi.00281.2016. Epub 2017 Jan 19.
5
A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients.持续皮下注射胰高血糖素样肽2（GLP-2）与进餐相关注射GLP-2对短肠综合征（SBS）患者治疗效果的剂量等效性比较。
Regul Pept. 2013 Jun 10;184:47-53. doi: 10.1016/j.regpep.2013.03.023. Epub 2013 Mar 15.
6
Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.胰高血糖素样肽2类似物替度鲁肽对接受家庭肠外营养的短肠综合征成年患者胃肠运动功能和通透性的急性影响
JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1089-1095. doi: 10.1177/0148607115597644. Epub 2015 Jul 28.
7
Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.格列帕利肽，一种新型的胰高血糖素样肽-2 激动剂，在大鼠炎症性肠病的实验模型中具有抗炎和黏膜再生作用。
BMC Gastroenterol. 2023 Mar 21;23(1):79. doi: 10.1186/s12876-023-02716-4.
8
The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease.靶向胃肠道疾病中胰高血糖素样肽-2 受体的治疗潜力。
Expert Opin Ther Targets. 2011 May;15(5):637-46. doi: 10.1517/14728222.2011.556620. Epub 2011 Feb 11.
9
Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study.胰高血糖素样肽（GLP）-1、GLP-2 及二者联合（GLP-1+GLP-2）持续输注对短肠综合征（SBS）患者肠道吸收的急性影响。一项安慰剂对照研究。
Regul Pept. 2013 Jun 10;184:30-9. doi: 10.1016/j.regpep.2013.03.025. Epub 2013 Mar 16.
10
Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.替度鲁肽，一种用于治疗胃肠道疾病（包括短肠综合征）的胰高血糖素样肽-2类似物。
Curr Opin Mol Ther. 2010 Dec;12(6):798-809.
引用本文的文献
1
The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂在合并代谢性共病的炎症性肠病患者的IBD相关手术及IBD相关并发症中的作用：一项系统评价和荟萃分析
Front Med (Lausanne). 2025 Aug 21;12:1621958. doi: 10.3389/fmed.2025.1621958. eCollection 2025.
2
Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis.大麻二酚增强奥沙拉嗪和环孢素在小鼠结肠炎模型中的治疗效果。
Int J Mol Sci. 2025 Aug 16;26(16):7913. doi: 10.3390/ijms26167913.
3
Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review.胰高血糖素样肽1（GLP-1）在炎症性肠病中的相关性：一项叙述性综述
Curr Issues Mol Biol. 2025 May 21;47(5):383. doi: 10.3390/cimb47050383.
4
Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.靶向内源性大麻素系统：一种治疗炎症性肠病肠外并发症的新方法。
Pharmaceuticals (Basel). 2025 Mar 27;18(4):478. doi: 10.3390/ph18040478.
5
Glucagon-Like Peptide-1 Is Prognostic of Mortality in Acute Respiratory Failure.胰高血糖素样肽-1对急性呼吸衰竭患者的死亡率具有预后价值。
Crit Care Explor. 2025 Mar 24;7(4):e1247. doi: 10.1097/CCE.0000000000001247. eCollection 2025 Apr 1.
6
Efficacy of three modern anti-diabetic drugs on survival outcomes of lung cancer patients with type 2 diabetes in China.三种现代抗糖尿病药物对中国2型糖尿病肺癌患者生存结局的疗效
Front Oncol. 2025 Feb 18;15:1498927. doi: 10.3389/fonc.2025.1498927. eCollection 2025.
7
Enhancing Tetrahydrocannabinol's Therapeutic Efficacy in Inflammatory Bowel Disease: The Roles of Cannabidiol and the Cannabinoid 1 Receptor Allosteric Modulator ZCZ011.增强四氢大麻酚在炎症性肠病中的治疗效果：大麻二酚和大麻素1受体变构调节剂ZCZ011的作用
Pharmaceuticals (Basel). 2025 Jan 23;18(2):148. doi: 10.3390/ph18020148.
8
Protective effect of Dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-β/PI3K/NF-κB signaling pathway.胰高血糖素样肽-1激动剂度拉糖肽对大鼠乙酸诱导的溃疡性结肠炎的保护作用：GLP-1、三叶因子3及TGF-β/PI3K/NF-κB信号通路的参与
Naunyn Schmiedebergs Arch Pharmacol. 2025 May;398(5):5611-5628. doi: 10.1007/s00210-024-03631-5. Epub 2024 Nov 23.
9
Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders.胰高血糖素样肽-1（GLP-1）激动剂在2型糖尿病及相关代谢紊乱管理中的最新进展和治疗益处
Cureus. 2024 Oct 21;16(10):e72080. doi: 10.7759/cureus.72080. eCollection 2024 Oct.
10
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.胰高血糖素样肽-1 受体：作用机制与治疗进展。
Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z.
本文引用的文献
1
Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients.评价低剂量利拉鲁肽在控制台湾非糖尿病患者体重方面的疗效。
J Diabetes Investig. 2020 Nov;11(6):1524-1531. doi: 10.1111/jdi.13314. Epub 2020 Jul 17.
2
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.利拉鲁肽治疗肥胖青少年的随机对照试验。
N Engl J Med. 2020 May 28;382(22):2117-2128. doi: 10.1056/NEJMoa1916038. Epub 2020 Mar 31.
3
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.195 个国家和地区 1990-2017 年炎症性肠病的全球、区域和国家负担：2017 年全球疾病负担研究的系统分析。
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4. Epub 2019 Oct 21.
4
Gastrointestinal peptides and small-bowel hypomotility are possible causes for fasting and postprandial symptoms in active Crohn's disease.胃肠道肽和小肠低动力可能是活动期克罗恩病空腹和餐后症状的原因。
Am J Clin Nutr. 2020 Jan 1;111(1):131-140. doi: 10.1093/ajcn/nqz240.
5
Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.GLP-1RA 治疗 2 型糖尿病患者的恶性肿瘤风险：一项荟萃分析。
J Diabetes Res. 2019 Jul 16;2019:1534365. doi: 10.1155/2019/1534365. eCollection 2019.
6
Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.胰高血糖素样肽在炎症性肠病中的作用：现有知识和未来展望。
Naunyn Schmiedebergs Arch Pharmacol. 2019 Nov;392(11):1321-1330. doi: 10.1007/s00210-019-01698-z. Epub 2019 Jul 29.
7
Celiac disease: a comprehensive current review.乳糜泻：全面的最新综述。
BMC Med. 2019 Jul 23;17(1):142. doi: 10.1186/s12916-019-1380-z.
8
Micronutrient Absorption and Related Outcomes in People with Inflammatory Bowel Disease: A Review.炎症性肠病患者的微量营养素吸收及相关结局：综述。
Nutrients. 2019 Jun 20;11(6):1388. doi: 10.3390/nu11061388.
9
Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 When Combined With Sitagliptin in Men.在男性中，沙库巴曲缬沙坦与西格列汀联合使用时可提高餐后活性胰高血糖素样肽-1的血浆浓度。
J Clin Endocrinol Metab. 2019 Sep 1;104(9):3868-3876. doi: 10.1210/jc.2019-00515.
10
Simultaneous analyses of carbohydrate-mediated serum GLP-1 and GLP-2 and duodenal receptor expression in children with and without celiac disease.对患有和未患有乳糜泻的儿童同时进行碳水化合物介导的血清胰高血糖素样肽-1和胰高血糖素样肽-2以及十二指肠受体表达的分析。
Therap Adv Gastroenterol. 2019 Apr 17;12:1756284819842756. doi: 10.1177/1756284819842756. eCollection 2019.
Zotero 插件